Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Editas Medicine, Inc.EDIT · Entity 5502 | Chief Technology Officer | March 18, 2019 | March 20, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Editas Medicine, Inc.
Report date March 18, 2019 · Filed March 20, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-03-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-03-18 · Exercise / conversion · Acquired 3,000 · Balance 3,000 F1: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. Row 2 · 2019-03-18 · Sale · Disposed 3,000 · Balance 0 F1: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.65 · Expires 2025-04-29 | Direct | 73,307 |
Reported balance
After 2019-03-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-03-18 · Exercise / conversion · Disposed 3,000 · Balance 73,307 F1: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. F2: This option was granted on April 30, 2015 and is scheduled to vest over four years, with 25% of the shares having vested on April 21, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through April 21, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017.
F2: This option was granted on April 30, 2015 and is scheduled to vest over four years, with 25% of the shares having vested on April 21, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through April 21, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 18, 2018 Filed Jul 19, 2018 20:07 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $11.21 | $0.00 |
DisclosureSEC source: 0001179110-18-009834 · edgar.xml · derivative · entry 10 Myer Vickesh · CIK 0001742806 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,897 Underlying: Common Stock · 7,000 shares Expires 2025-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. F5 · derivative.exercise_date: This option was granted on October 30, 2015 and is scheduled to vest over four years with 25% of the shares having vested on October 27, 2016, and the remaining 75% of the shares schedule to vest in equal monthly installments thereafter through October 27, 2019. Read SEC document |
| July 18, 2018 Filed Jul 19, 2018 20:07 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 850 | $36.25 | $30,812.50 |
DisclosureSEC source: 0001179110-18-009834 · edgar.xml · nonDerivative · entry 8 Myer Vickesh · CIK 0001742806 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $36.12 to $36.45. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 18, 2018 Filed Jul 19, 2018 20:07 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionCommon Stock | 850 | $11.21 | $9,528.50 |
DisclosureSEC source: 0001179110-18-009834 · edgar.xml · nonDerivative · entry 7 Myer Vickesh · CIK 0001742806 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. Read SEC document |
| July 18, 2018 Filed Jul 19, 2018 20:07 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 6,150 | $35.46 | $218,079.00 |
DisclosureSEC source: 0001179110-18-009834 · edgar.xml · nonDerivative · entry 6 Myer Vickesh · CIK 0001742806 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.11 to $36.10. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 18, 2018 Filed Jul 19, 2018 20:07 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionCommon Stock | 6,150 | $11.21 | $68,941.50 |
DisclosureSEC source: 0001179110-18-009834 · edgar.xml · nonDerivative · entry 5 Myer Vickesh · CIK 0001742806 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 20:07 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001179110-18-009834 · edgar.xml · derivative · entry 9 Myer Vickesh · CIK 0001742806 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,307 Underlying: Common Stock · 7,000 shares Expires 2025-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. F4 · derivative.exercise_date: This option was granted on April 30, 2015 and is scheduled to vest over four years with 25% of the shares having vested on April 21, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through April 21, 2019. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 20:07 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 4,000 | $36.50 | $146,000.00 |
DisclosureSEC source: 0001179110-18-009834 · edgar.xml · nonDerivative · entry 4 Myer Vickesh · CIK 0001742806 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 20:07 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionCommon Stock | 4,000 | $0.65 | $2,600.00 |
DisclosureSEC source: 0001179110-18-009834 · edgar.xml · nonDerivative · entry 3 Myer Vickesh · CIK 0001742806 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 20:07 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 3,000 | $34.66 | $103,980.00 |
DisclosureSEC source: 0001179110-18-009834 · edgar.xml · nonDerivative · entry 2 Myer Vickesh · CIK 0001742806 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 20:07 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionCommon Stock | 3,000 | $0.65 | $1,950.00 |
DisclosureSEC source: 0001179110-18-009834 · edgar.xml · nonDerivative · entry 1 Myer Vickesh · CIK 0001742806 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:57 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $11.21 | $0.00 |
DisclosureSEC source: 0001179110-18-008837 · edgar.xml · derivative · entry 8 Myer Vickesh · CIK 0001742806 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,897 Underlying: Common Stock · 7,000 shares Expires 2025-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. F6 · derivative.exercise_date: This option was granted on October 30, 2015 and is scheduled to vest over four years with 25% of the shares having vested on October 27, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through October 27, 2019. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:57 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 7,000 | $38.39 | $268,730.00 |
DisclosureSEC source: 0001179110-18-008837 · edgar.xml · nonDerivative · entry 6 Myer Vickesh · CIK 0001742806 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $38.00 to $38.95. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:57 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionCommon Stock | 7,000 | $11.21 | $78,470.00 |
DisclosureSEC source: 0001179110-18-008837 · edgar.xml · nonDerivative · entry 5 Myer Vickesh · CIK 0001742806 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. Read SEC document |
| June 18, 2018 Filed Jun 20, 2018 20:57 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001179110-18-008837 · edgar.xml · derivative · entry 7 Myer Vickesh · CIK 0001742806 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,307 Underlying: Common Stock · 7,000 shares Expires 2025-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. F5 · derivative.exercise_date: This option was granted on April 30, 2015 and is scheduled to vest over four years with 25% of the shares having vested on April 21, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through April 21, 2019. Read SEC document |
| June 18, 2018 Filed Jun 20, 2018 20:57 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 2,700 | $38.71 | $104,517.00 |
DisclosureSEC source: 0001179110-18-008837 · edgar.xml · nonDerivative · entry 4 Myer Vickesh · CIK 0001742806 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $38.35 to $38.92. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 18, 2018 Filed Jun 20, 2018 20:57 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionCommon Stock | 2,700 | $0.65 | $1,755.00 |
DisclosureSEC source: 0001179110-18-008837 · edgar.xml · nonDerivative · entry 3 Myer Vickesh · CIK 0001742806 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. Read SEC document |
| June 18, 2018 Filed Jun 20, 2018 20:57 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 4,300 | $37.75 | $162,325.00 |
DisclosureSEC source: 0001179110-18-008837 · edgar.xml · nonDerivative · entry 2 Myer Vickesh · CIK 0001742806 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.34 to $38.32. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 18, 2018 Filed Jun 20, 2018 20:57 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | Exercise / conversionCommon Stock | 4,300 | $0.65 | $2,795.00 |
DisclosureSEC source: 0001179110-18-008837 · edgar.xml · nonDerivative · entry 1 Myer Vickesh · CIK 0001742806 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.